Continuation Study for Latozinemab
← catalyst calendarSponsored by Alector Inc. (industry) · ALEC — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
17actual
Sites
18
Countries
Belgium, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-08 | actual | When the study began enrolling |
| Primary completion | 2025-09-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-07 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neurodegenerative Diseases
Intervention
- Drug: Latozinemab — also filed as AL001
Primary outcomes
what the primary-completion date above is the date OFNumber of participants receiving latozinemab
measured Through study completion, up to 190 weeks
Duration of treatment with latozinemab
measured Through study completion, up to 190 weeks
Permalink · ALEC's whole pipeline · Catalyst calendar · Every registered study · What changed